Patterns of factor prophylaxis in the Canadian hemophilia A population

Outcome measures in haemophilia: more than just factor levels

“…In support of this, data from the Canadian Blood Services and Haema‐Quebec demonstrate that the demand for rFVIII is increasing by 5–10% per year. Furthermore, 57.5% of rFVIII in Canada is used for prophylaxis and immune tolerance induction therapy [8].…”